A new cancer therapy, known as SABR (Stereotactic Body Radiation Therapy), is becoming available to thousands of men across the UK diagnosed with prostate cancer. Previously used for lung and brain cancers, SABR offers a less invasive and highly targeted treatment option. The therapy delivers precise radiation doses directly to the tumor, minimizing damage to surrounding healthy tissue. This advancement aims to improve outcomes and reduce side effects compared to traditional treatments. Patient experience with this therapy is being closely monitored, with early results showing promise. Wider access to SABR represents a significant step forward in prostate cancer care within the National Health Service.